Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2969262 | 0.92 | SMN1; SMN2 (0.66) | SMN1; SMN2LMNAALDH1A1GAAMAOB | |
| SCHEMBL2975895 | 0.86 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAALDH1A1GAAMAOB | |
| SCHEMBL2963177 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNAALDH1A1GAAMAOB | |
| SCHEMBL2969374 | 0.82 | SMN1; SMN2 (0.74) | SMN1; SMN2LMNAALDH1A1GAAMAOB | |
| SCHEMBL6573523 | 0.77 | LMNA (0.72) | SMN1; SMN2LMNAALDH1A1GAAMAOB | |
| SCHEMBL3576339 | 0.77 | KMT2A (0.43) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL13338211 | 0.77 | KMT2A (0.43) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL26757979 | 0.77 | SMN1; SMN2 (0.78) | SMN1; SMN2LMNAALDH1A1GAAMAOB | |
| SCHEMBL14278716 | 0.77 | KMT2A (0.43) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL3568621 | 0.77 | KMT2A (0.43) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776924-B2 | Nitroaniline-based alkylating agents and their use as prodrugs | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-08-17 | — | — | US | disclosed |
| US-20050256191-A1 | Nitroaniline-based alkylating agents and their use as prodrugs | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256191-A1 | Nitroaniline-based alkylating agents and their use as prodrugs | IDH3A, HIF1AN, IDH1 | SMN1; SMN2 2843/4885LMNA 3875/4885ALDH1A1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.